drugset / Trial / NCT04307797
Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes
Phase 4
Completed
10 enrolled
Cambridge University Hospitals NHS Foundation Trust
Antaros Medical · collab
RandomizedSingle-groupSingle-blindBasic science
Summary
The study seeks to explore the cardiovascular effects of co-agonism at the glucagon and (glucagon-like peptide-1) GLP-1 receptor. Glucagon and exenatide will be intravenously infused into participants with type 2 diabetes (T2DM). Overall, the aim of the study is to further the investigator's understanding on the role these endogenous substances have on normal cardiac physiology, myocardial energetics and myocardial glucose uptake through a series of PET and MRI imaging studies
Timeline
- Start
- 2022-01-18
- Primary completion
- 2022-10-07
- Completion
- 2022-10-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Exenatide | Peptide | 25 ng | Intravenous |
| Subject | Glucagon | Peptide | 0.0125 ug/kg | Intravenous |